ACALABRUTINIB

acalabrutinib 100 mg tablet, 56

ACALABRUTINIB (15360K)

acalabrutinib 100 mg tablet, 56
15360K
Manner of administration:Oral
General Schedule
Authority Required

Restriction

Indication: Chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL)
Treatment phase: Initial treatment (treatment cycles 1 to 2 inclusive) in first-line therapy
Quantities & Cost
Max qty packs Max qty units # of repeats DPMQ Max safety net General Patient Charge
Max qty packs: 1 Max qty units: 56 # of repeats: 1 DPMQ: $7,052.30 Max safety net: $25.00 General Patient Charge: $25.00
Available brands
CALQUENCE